-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
-
Summary
-
Inovio Pharmaceuticals, Inc. quarterly/annual Revenue from Contract with Customer, Excluding Assessed Tax history and growth rate from Q1 2017 to Q2 2025.
- Inovio Pharmaceuticals, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending June 30, 2025 was $0.000, a 100% decline year-over-year.
- Inovio Pharmaceuticals, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the twelve months ending June 30, 2025 was $182K, a 69.2% decline year-over-year.
- Inovio Pharmaceuticals, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2024 was $218K, a 73.8% decline from 2023.
- Inovio Pharmaceuticals, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2023 was $832K, a 91.9% decline from 2022.
- Inovio Pharmaceuticals, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $10.3M, a 478% increase from 2021.
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Growth (%)